Literature DB >> 8012690

A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.

A Roccon1, D Marchionni, F Donat, D Segondy, C Cazaubon, D Nisato.   

Abstract

1. Conscious normotensive cynomolgus monkeys were chronically instrumented for the measurement of arterial blood pressure and heart rate to investigate the relationships between the plasma concentration, suppression of the pressor response to angiotensin II (AII), compensatory increase in plasma AII, and hypotensive effect obtained after a single oral dose of SR 47436, a potent and specific nonpeptide AT1 receptor antagonist. As blood sampling could influence the hypotensive effect of SR 47436 through activation of the renin angiotensin system (RAS), drug effects were studied in groups of animals with or without blood samplings. 2. SR 47436 at 10 mg kg-1 induced a hypotensive effect which was not greater following a second dose of 30 mg kg-1, indicating that a maximal hypotensive effect had already been obtained. 3. A single oral dose of SR 47436 (10 mg kg-1) caused a sustained hypotension and a marked inhibition of the AII-induced pressor response, lasting for up to 28 h. These effects of SR 47436 are consistent with good oral bioavailability and a slow elimination of the drug (t 1/2 approximately 20 h), and were accompanied by a sustained increase in plasma AII concentration. Taken together, both the hypotensive response and the compensatory increase in AII indicated that vascular and juxtaglomerular AII receptors were blocked. 4. Although a fair correlation between individual plasma drug concentrations and inhibition of AII-induced pressor response was observed, neither the hypotensive effect nor the compensatory increase in AII correlated with the plasma drug levels. 5. Basal arterial pressure and AII-induced pressor response were not affected by blood samplings. 6. These results suggest that SR 47436 is an effective and long lasting AT1 receptor antagonist with a potent hypotensive action in normotensive cynomolgus monkeys. It may be an efficacious blocker of the RAS in man and suitable for once-a-day dosing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8012690      PMCID: PMC1910027          DOI: 10.1111/j.1476-5381.1994.tb14036.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Direct, simplified, and sensitive assay of angiotensin II in plasma extracts performed with a high-affinity monoclonal antibody.

Authors:  D Simon; B Romestand; H Huang; G Badouaille; J A Fehrentz; B Pau; J Marchand; P Corvol
Journal:  Clin Chem       Date:  1992-10       Impact factor: 8.327

2.  1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.

Authors:  J Weinstock; R M Keenan; J Samanen; J Hempel; J A Finkelstein; R G Franz; D E Gaitanopoulos; G R Girard; J G Gleason; D T Hill
Journal:  J Med Chem       Date:  1991-04       Impact factor: 7.446

Review 3.  Various approaches to blockade of the renin-angiotensin system: persistent renin response.

Authors:  H R Brunner; J Nussberger; B Waeber
Journal:  J Hypertens Suppl       Date:  1990-12

4.  Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X.

Authors:  P C Wong; W A Price; A T Chiu; J V Duncia; D J Carini; R R Wexler; A L Johnson; P B Timmermans
Journal:  Hypertension       Date:  1990-05       Impact factor: 10.190

5.  Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.

Authors:  A T Chiu; D E McCall; W A Price; P C Wong; D J Carini; J V Duncia; R R Wexler; S E Yoo; A L Johnson; P B Timmermans
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

6.  Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.

Authors:  A Munafo; Y Christen; J Nussberger; L Y Shum; R M Borland; R J Lee; B Waeber; J Biollaz; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

7.  Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

Authors:  Y Christen; B Waeber; J Nussberger; M Porchet; R M Borland; R J Lee; K Maggon; L Shum; P B Timmermans; H R Brunner
Journal:  Circulation       Date:  1991-04       Impact factor: 29.690

Review 8.  Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems.

Authors:  P R Saxena
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

9.  Angiotensin II receptor subtypes in renal cortex of rats and rhesus monkeys.

Authors:  R E Gibson; H H Thorpe; M E Cartwright; J D Frank; T W Schorn; P B Bunting; P K Siegl
Journal:  Am J Physiol       Date:  1991-09

Review 10.  Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial?

Authors:  N R Levens; M de Gasparo; J M Wood; S P Bottari
Journal:  Pharmacol Toxicol       Date:  1992-10
View more
  2 in total

1.  Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

Authors:  Venkata V Pavan Kumar; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

2.  Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.

Authors:  R Cirillo; A R Renzetti; P Cucchi; M Guelfi; A Salimbeni; S Caliari; A Castellucci; S Evangelista; A Subissi; A Giachetti
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.